Leaflet DEFERASIROX ZENTIVA 360mg film-coated tablets


Indicated for: iron overload

Substance: deferasirox (chelating agent)

ATC: V03AC03 (Various | All other therapeutic products | Iron chelating agents)

Deferasirox is an iron chelator used for the treatment of chronic iron overload in patients with frequent blood transfusions, such as those with major thalassemia. It works by binding excess iron, facilitating its elimination through feces.

The medication is taken orally, usually once daily, with the dose adjusted based on the body's iron levels and the patient's weight. Common side effects include nausea, diarrhea, abdominal pain, and elevated liver enzymes.

Deferasirox is contraindicated in patients with severe renal impairment, hepatic failure, or hypersensitivity to the active substance. Its use also requires regular monitoring of renal and hepatic function.

This medication is an effective option for managing iron overload, helping to prevent complications associated with this condition.

General data about DEFERASIROX ZENTIVA 360mg

  • Substance: deferasirox
  • Date of last drug list: 01-12-2020
  • Commercial code: W66993001
  • Concentration: 360mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 30
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: ZENTIVA K.S. - REPUBLICA CEHA
  • Holder: ZENTIVA K.S. - REPUBLICA CEHA
  • Number: 13287/2020/01
  • Shelf life: 2 years

Pharmaceutical forms available for deferasirox

Concentrations available for deferasirox

  • 125mg
  • 180mg
  • 250mg
  • 360mg
  • 500mg
  • 90mg